Compare AU
Compare CURE vs. HVST
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the BetaShares Australian Dividend Harvester Fund (Managed Fund) (HVST). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | HVST | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 83 | 52 |
Median incremental investment | $619.50 | $993.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,437.24 | $3,228.71 |
Average age group | > 35 | > 35 |
Key Summary
CURE | HVST | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | HVST.AX was created on 2014-10-29 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 226.57m in AUM and 54 holdings. HVST.AX aims to provide exposure to large-cap Australian shares, along with the potential for franked income that is at least 1.5x the yield of the Australian broad sharemarket on an annual basis. |
Top 3 holdings | Natera Inc (3.33 %) Incyte Corp (2.95 %) Gilead Sciences Inc (2.81 %) | BETASHARES AUSTRALIA 200 ETF (24.70 %) COMMONWEALTH BANK OF AUSTRALIA (10.55 %) BETASHARES AUSTRALIAN RESOURCE (9.04 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Other (47.20 %) Financials (16.27 %) Health Care (6.88 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | Australia (97.05 %) United States (2.00 %) United Kingdom of Great Britain and Northern Ireland (0.56 %) |
Management fee | 0.45 % | 0.65 % |
Key Summary
CURE | HVST | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.65 % |
Price | $51.33 | $13.71 |
Size | $36.301 million | $233.803 million |
10Y return | N/A | -45.38 % |
Annual distribution yield (5Y) | 4.24 % | 9.09 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 03/11/2014 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | HVST | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 83 | 52 |
Median incremental investment | $619.50 | $993.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,437.24 | $3,228.71 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | HVST | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | HVST |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |